pathway have shown efficacy in some patients with advanced cancers, a deeper knowledge of coordinated immunosuppression in the PD-L1+ tumor microenvironment is needed to improve upon these therapeutic results. Here we show that PD-L1+ melanomas over-express PD-1, LAG-3, IL-10, and IL-32, which may contribute to local immunosuppression and therefore are candidates for co-targeting in combination treatment regimens. This study further reveals factors that selectively induce PD-L1 on myeloid cells but not tumor cells, and thus begins to elucidate novel mechanisms for PD-L1 up-regulation in the tumor microenvironment. 
INTRODUCTION
Programmed death ligand 1 (PD-L1, B7-H1) expression by antigen presenting cells (APCs) is a normal feedback mechanism for terminating immune responses appropriately and maintaining self-tolerance. 1 Aberrant PD-L1 expression in cancers coopts this mechanism, facilitating escape from immune attack. PD-1, the dominant receptor for PD-L1, is found on activated T, B and NK cells in the tumor microenvironment (TME). Its ligation by PD-L1 down-modulates anti-tumor immune effector functions. Antibodies (mAbs) interrupting the PD-1 pathway, blocking either PD-1 or PD-L1, have durable efficacy in patients with advanced melanoma and other cancers, further highlighting the key role of this pathway in local tumor immunosuppression. 2, 3 Multiple studies using different detection methods and analytic criteria have demonstrated that PD-L1 expression on tumor cells and/or leukocytes in the TME may predict response to PD-1 pathway blockade. In some cancers, such as MSI colon cancer, PD-L1 is expressed predominantly on tumor-infiltrating monocytic cells rather than on tumor cells themselves, 4 whereas we reported that PD-L1+ melanomas and head and neck cancers express PD-L1 on both tumor and monocytic cells. 5, 6 A recent study suggests that leukocyte expression of PD-L1 is most predictive of response to an anti-PD-L1 antibody. 7 Therefore, understanding TME factors that coordinately influence PD-L1 expression on tumor cells and/or leukocytes is essential to augmenting the clinical impact of anti-PD-1/PD-L1 therapies. Such factors may warrant further study as candidate biomarkers of clinical outcomes to PD-1 blockade, or as co-targets for developing synergistic combination therapies with anti-PD-1/PD-L1.
METHODS

Melanoma specimens
Forty-nine formalin-fixed paraffin-embedded (FFPE) melanoma specimens were characterized for PD-L1 expression by immunohistochemistry (IHC) as described, presence of TILs was also noted, and TILs were scored as none (0), mild (1), moderate (2) , or severe (3) in intensity, as previously described. 5 Eleven specimens were subjected to laser capture microdissection (LCM) followed by cDNA-mediated Annealing, Selection, extension and Ligation (DASL) microarray to profile differential gene expression between 5 PD-L1+ and 6 PD-L1(-) melanomas. Another set of eleven specimens, including 4 specimens previously assessed with microarray and 7 new cases, was used to validate differential expression of candidate genes with quantitative (q)RT-PCR, including 6 PD-L1+ cases and 5 PD-L1(-) specimens with TIL intensities similar to the original set (detailed in Supplementary Methods). A separate cohort of 8 lymph node metastases was used to develop amplified in situ hybridization (ISH) detection methods for LAG3 expression, and 25 lymph node metastases were used to investigate geographic relationships between tumor cell PD-L1 expression and TIL LAG-3 expression with IHC. Six specimens were each included in two cohorts. Studies were approved by the Institutional Review Board at the Johns Hopkins University School of Medicine.
Laser capture microdissection (LCM) and RNA isolation
Tumor cells and neighboring immune infiltrates (lymphocytes and macrophages) were excised from FFPE melanoma specimens with LCM, avoiding necrotic areas.
RNA was isolated as previously described using the High Pure RNA Paraffin Kit (Roche Diagnostics, Indianapolis, IN). 5 For PD-L1+ tumors, IHC on neighboring tissue sections was used to identify areas of PD-L1 expression for excision. For PD-L1(-)tumors, regions of tumor and associated infiltrating immune cells were sampled.
Whole genome microarray analysis
Gene expression was detected by DASL assays arrayed on the Illumina Human HT-12 WG-DASL V4.0 R2 expression bead chip (GEO platform GPL14951), per the manufacturer's specifications. This platform detects 29,377 annotated transcripts and is designed to detect partially degraded mRNAs such as typically found in FFPE tissue specimens. 8 Briefly, mRNA isolated from melanoma specimens was reverse transcribed and amplified by PCR using universal primers. PCR products were denatured and hybridized to the Illumina array, washed and scanned to obtain gene expression intensity data. A single intensity (expression) value for each Illumina probe on the DASL array was obtained using Illumina GenomeStudio software with standard settings and no background correction (the dataset is available at NCBI's Gene Expression Omnibus under the GEO Series accession number GSE65041). Based on examining the histograms of the expression values for each sample, which were generally bimodal, a probe was considered to be Present in a given sample if its corresponding expression value was at or above 1024 (2 10 ), and no normalization was performed. The expression values for all probes and samples were log (base 2) transformed before performing statistical analysis. Analysis for differential expression was carried out for each Illumina microarray probe. Lists of genes passing specified distinguishing criteria were examined for significant enrichment in gene annotation categories, and in functionally related categories including KEGG pathways, using the DAVID web tool (http://david.abcc.ncifcrf.gov/). 9.10 Additional details are provided in Supplementary Methods.
Multiplex qRT-PCR
Total RNA from each melanoma specimen was reverse-transcribed, preamplified, and added to TaqMan Array Micro Fluidic cards per protocol (Applied Biosystems, Foster City, CA) (see Supplementary Methods). These cards were customdesigned with 64 gene-specific primers/probes in triplicate, including internal controls (Supplementary Table S1 ). PCRs were run using a 7900 HT Fast Real Time PCR system, and data analysis and display were performed using the manufacturer's software (Applied Biosystems). Analysis was based on tumor PD-L1 expression status (positive or negative by IHC), using the manufacture's software.
Analysis of lymphocyte activation gene 3 (LAG-3) expression in tissue sections
LAG-3 protein expression was analyzed in 5-um-thick FFPE tissue sections by IHC. Antigen retrieval was performed at 120 o C for 10 min in citrate buffer, pH 6.0.
Primary anti-LAG-3 mAb (murine anti-human clone 17B4, LS Bio, Seattle, WA) was used at a concentration of 1.0 ug/mL and incubated for 2 hours at room temperature. An 
Recombinant cytokines and chemokines
Commercially available recombinant human cytokines and chemokines were added to cell cultures at final concentrations of 100 or 250 ng/ml, except interferongamma (IFN-g) which was used at 100 or 250 IU/ml. These concentrations were selected as biologically active based on published literature. IL-10, CCL5 (RANTES), and CXCL1 were purchased from Peprotech (Rocky Hill, NJ); IL-18, IL-32-a, and IL-32-g from R&D Systems (Minneapolis, MN); and IL-21 from GIBCO (Frederick, MD). IFN-g was obtained from Biogen (Cambridge, MA).
Effects of cytokines and chemokines on PD-L1 expression by cultured melanomas
Cultured melanoma cells were seeded into 24-well plates at 50% confluence and allowed to adhere for at least 24 hours. Then they were cultured under 3 conditions: without cytokines, with individual cytokines or chemokines, or with a combination of IFN-g plus each cytokine or chemokine. Cells were harvested after 1, 2, or 3 days and co-stained with mAbs specific for PD-L1 (clone MIH1) and HLA-DR (clone L243), or isotype-matched negative control antibodies. Treatment with IFN-g alone provided a positive control for promoting PD-L1 and HLA-DR expression by melanoma cells.
Effects of cytokines and chemokines on PD-1/PD-L1 expression by human PBMCs (T cells and monocytes)
Unseparated PBMCs were cultured in 24-well plates (1.5-2.0e To determine the effects of IL-32-g on T cells in the absence of monocytes, CD3+ cells were isolated (>98% purity) and cultured with or without anti-CD3/CD28 stimulation in the presence or absence of IL-32-g (100 ng/ml) for 1 or 3 days. Cells were then co-stained for CD8 or CD4, and the following markers: PD-1, PD-L1, and CD69. To investigate the effects of IL-10 and IL-32-g on monocytes in the absence of lymphocytes, monocytes were enriched by plastic adherence and cultured under the following conditions: 1) no cytokines; 2) IFN-g alone (100 or 250 IU/ml); 3) IL-10 alone or IL-32-g alone (100 ng/ml); and 4) IFN-g plus either IL-10 or IL-32-g. After two days, cells were collected and co-stained for CD14 and the following markers: PD-1, PD-L1, PD-L2 (clone MIH18), CD86, and HLA-DR.
Flow cytometric analysis
Non-specific mouse IgG (Life Technologies) was used to block Fc receptors on PBMCs and enriched monocytes. All fluorochrome-conjugated specific mAbs and their isotype-matched controls were purchased from BD Biosciences (San Jose, CA) or eBioscience (San Diego, CA). Samples were acquired on the BD FACSCalibur and data were analyzed with FlowJo Software (TreeStar, Ashland, OR).
RESULTS
Whole genome microarray and functional clustering analysis
To identify genes differentially expressed between PD-L1+ and (-) melanomas, LCM was used to precisely capture boundary areas containing tumor cells and TILs Table S2 ) was submitted to the NIH DAVID database for functional annotation clustering. Twelve resulting categories containing ≥10 distinct genes from this list and having a Benjamini-Hochberg adjusted p-value (FDR) <0.015 were obtained. Also consistent with previous studies, PDCD1 (PD-1) was over-expressed in the PD-L1+ TME. 13 Other immunosuppressive molecules coordinately expressed with CD274 included IL10 and LAG3.
LAG-3 over-expression in the PD-L1+ tumor immune microenvironment
The coordinate expression of the LAG3 immune checkpoint with CD274, detected on mRNA analysis, was further explored on a protein level with IHC in a cohort of 25 melanoma lymph node metastases. Eleven of 12 cases (92%) demonstrating tumor cell PD-L1 protein expression at the interface between tumor and lymphocytes also showed LAG-3 protein expression by at least 5% of those lymphocytes (Figure 3,   Supplementary Figure S1 ). In contrast, only 2 of 13 (15%) cases that were PD-L1(-) expressed LAG-3 (p=0.0002, Fisher's Exact Test). Thus, LAG-3+ TILs significantly colocalized with PD-L1+ melanoma cells. LAG3 mRNA expression in melanoma tissue sections was also detected with amplified ISH and was compared to protein expression on IHC. In all 8 melanoma lymph node metastases examined, the density and location of lymphocytes expressing LAG-3 by IHC correlated with ISH results (Supplementary Figure S2) .
Impact of cytokines and chemokines on melanoma cell expression of PD-L1
Several cytokines and chemokines that were over-expressed in the PD-L1+ melanoma microenvironment were tested in vitro for their potential effects on PD-L1 expression by three melanoma cell lines. These recombinant proteins included CCL5 (RANTES), CXCL1, IL-10, IL-18, and IL-21 (Supplementary Table S5 ). In addition, the alpha and gamma isoforms of IL-32 were assessed in vitro. IL32 mRNA, detected by one of two probes in the whole genome microarray recognizing a shared sequence in all IL32 isoforms, was up-regulated 15-fold in PD-L1+ melanomas (p=0.014) (Supplementary Table S2) ; although this was not validated by qRT-PCR, the available commercial probe detected a different region of IL32. The melanomas 537-mel, 1363-mel and 1558-mel, known to up-regulate cell surface PD-L1 and HLA-DR protein expression in response to IFN-g exposure in vitro, 5 were incubated with each recombinant protein at 100 or 250 ng/ml, with or without IFN-g at 100 IU/ml. Notably, none of these individual factors or combinations affected the intensity of melanoma cell surface PD-L1 or HLA-DR expression after 1, 2 or 3 days of culture (not shown).
Additionally, at 6 days, no effects were observed on melanoma proliferation. Therefore, these factors did not appear to directly affect melanoma cell expression of PD-L1 in vitro.
Impact of cytokines and chemokines on immune cell expression of PD-1 and its ligands
We next investigated the potential effects of factors over-expressed in PD-L1+ melanomas, on immune cell expression of PD-1 and its ligands. PBMCs were cultured 14 However, its expression in melanoma is characteristically associated with intratumoral immune infiltrates, a phenomenon termed "adaptive immune resistance". 5 IFN-g, a dominant product of human melanoma-specific TILs, is a major inducer of PD-L1 expression on tumor cells in vitro 15 and is selectively over-expressed in the milieu of PD-L1+ solid tumors including melanomas. 5, 6 The current study confirms an association of IFN-g with PD-L1+ melanomas and goes beyond this to explore other factors coordinately expressed in the PD-L1+ melanoma microenvironment. It reveals a complex landscape of interacting receptors, ligands and soluble factors which may be exploited to therapeutic advantage.
Several of the molecules that were found to be significantly over-expressed in PD-L1+ vs. PD-L1(-) melanomas are associated with activated CD8+ T cells (CD8A,
PRF1, IL18, IL21).
The observed co-expression of mRNAs encoding CD274 and CD8A is consistent with published reports detecting the co-localization of PD-L1+ melanoma cells with infiltrating CD8+ T cells by IHC. 16, 17 The presence of CD8+ TILs has recently been proposed as a biomarker of response to PD-1 blockade in melanoma. 16 In addition to markers of T cell activation, we also found evidence for over-expression of molecules associated with activated pro-inflammatory APCs, including CXCL1, TLR3, and LYZ. 
